marked.bio

Company

Wayshine Biopharm

2 active trials that select patients by a biomarker on marked.bio.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

WSD0922 2

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

    Recruiting Phase 2 Wayshine Biopharm Started 2025Primary completion 2027-09 NCT06868485

    WSD0922

    Documented EGFR mutation .

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

  2. A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

    Recruiting Phase 1/2 Wayshine Biopharm Started 2024Primary completion 2027-06 NCT06631989

    WSD0922

    A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

    EGFR exon 19 deletion / L858REGFR Mutation Positive Advanced Non-Small Cell Lung Cancer